> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AstraZeneca Discontinuing Lumoxiti for Hairy Cell Leukemia
- URL: https://www.fdaweb.com/astrazeneca-discontinuing-lumoxiti-for-hairy-cell-leukemia/
- Published: 2023-01-13T12:00:00.000Z
- Updated: 2026-09-14T18:11:47.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153537

AstraZeneca says it will permanently discontinue marketing and distributing Lumoxiti (moxetumomab pasudotox-tdfk) for injection 8/31\. It is indicated for treating adults with relapsed or refractory hairy cell leukemia. In a [company letter](https://www.fda.gov/media/164425/download?ref=fdaweb.com) to healthcare professionals, it notes the discontinuation decision was not related to any safety or effectiveness concern, rather since approval the therapy had experienced a "low clinical uptake.” This likely was caused by “the availability of other treatment options and possibly due to the specialized complexity of administration, toxicity prophylaxis and safety monitoring needs for patients,” it adds.